Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rochelle Y Benoit

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Immunology|February 26, 2026
Bruton's Tyrosine Kinase-Going Beyond the B CellRochelle Y Benoit, Sheila Loshi, Craig S Moore
Multiple Sclerosis and Related Disorders|September 20, 2022
Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?Shane Arsenault, Rochelle Y Benoit, Fraser Clift, et al.
Immunohorizons|September 11, 2024
Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid CellsRochelle Y Benoit, Jennifer L Zagrodnik, Samantha J Carew, et al.
Journal of Neurochemistry|May 28, 2022
Investigating the NLRP3 inflammasome and its regulator miR-223-3p in multiple sclerosis and experimental demyelinationDylan A Galloway, Samantha J Carew, Stephanie N Blandford, et al.
Nature Communications|August 28, 2023
Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseasesErik Nutma, Nurun Fancy, Maria Weinert, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Immunology|February 26, 2026
Bruton's Tyrosine Kinase-Going Beyond the B CellRochelle Y Benoit, Sheila Loshi, Craig S Moore
Multiple Sclerosis and Related Disorders|September 20, 2022
Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?Shane Arsenault, Rochelle Y Benoit, Fraser Clift, et al.
Immunohorizons|September 11, 2024
Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid CellsRochelle Y Benoit, Jennifer L Zagrodnik, Samantha J Carew, et al.
Journal of Neurochemistry|May 28, 2022
Investigating the NLRP3 inflammasome and its regulator miR-223-3p in multiple sclerosis and experimental demyelinationDylan A Galloway, Samantha J Carew, Stephanie N Blandford, et al.
Nature Communications|August 28, 2023
Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseasesErik Nutma, Nurun Fancy, Maria Weinert, et al.
Pageof 1